Posts by: Patricia Inacio, PhD

PBI-4050, Prometic Life Sciences’ lead small molecule therapy candidate, targets a new antifibrotic pathway involving two receptors that play opposite roles in fibrosis development, researchers found. The study, “A Newly Discovered ... Read more

February 20, 2018February 20, 2018

Synthetic Proteins That Mimic Enzyme HYAL2 May Be Potential Therapeutic Strategy for PF, Researchers Say

Idiopathic Pulmonary Fibrosis, News

Researchers found that an enzyme previously linked only to cell metabolism is capable of reaching the nucleus of lung fibroblasts and once there, halting the cells’ transition to myofibroblasts, the ... Read more

January 8, 2018January 8, 2018

Tackling Asthma’s Genetic Causes May Yield New Therapies and ID Higher-risk Patients, Yale Study Says

Asthma, News

More insight into the genetic causes of asthma may open new therapeutic avenues and help identify people at higher risk of developing the disease, say researchers at the Yale School of Public ... Read more

December 14, 2017December 14, 2017

Aggressive Surgery Increases Lung Cancer Patients’ Long-term Survival, Study Shows

Lung Cancer, News

A lung surgery called lobectomy increases early lung cancer patients’ long-term survival better than less aggressive surgical approaches or radiation, a study shows. A lobectomy involves removing portions of lungs ... Read more

November 28, 2017November 28, 2017

Weill Cornell Medicine Gets $2.1 Million to Study Gene’s Role in Lung and Kidney Fibrosis

Idiopathic Pulmonary Fibrosis, News

Weill Cornell Medicine in New York City has received a $2.1 million government grant to study a mechanism underlying lung and kidney scarring. The National Heart, Lung and Blood Institute grant will allow ... Read more

November 17, 2017November 17, 2017

Veracyte’s Genomic Tool Aids in Diagnosing IPF Without Surgery, Real-world Data Suggests

Idiopathic Pulmonary Fibrosis

Veracyte presented early data from a real-world clinical test showing that its Envisia Genomic Classifier is an efficient tool for diagnosing idiopathic pulmonary fibrosis (IPF) without invasive and expensive surgery. ... Read more

November 16, 2017November 16, 2017

Ofev Slows Scarring in Pulmonary Fibrosis Patients’ Lungs, Phase 3b Trial Shows

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim’s Ofev (nintedanib) slows scarring in idiopathic pulmonary fibrosis patients’ lungs, a Phase 3b trial indicates. The company used an imaging technique to check on Ofev’s anti-fibrotic properties. It was the ... Read more

November 2, 2017November 2, 2017

Experts Release New Guidelines for Lung Cancer Screening at CHEST 2017

Lung Cancer, News

In a manuscript published in the journal CHEST, a group of experts discuss recent evidence concerning the benefit, harms, and implementation of low-radiation dose chest computed tomography (CT) in lung cancer screening. ... Read more

November 1, 2017November 1, 2017

Prometic’s Pulmonary Fibrosis Therapy PBI-4050 Earns FDA Fast Track Status

Idiopathic Pulmonary Fibrosis

The U.S. Food and Drug and Drug Administration has awarded Fast Track status to PBI-4050, Prometic Life Sciences‘ treatment for lung scarring in idiopathic pulmonary fibrosis. The Fast Track designation ... Read more

October 19, 2017October 19, 2017

FDA Giving Priority Review to Gilotriftm as Treatment for Rare Form of Lung Cancer

Lung Cancer, News

The U.S. Food and Drug Administration is giving priority review to Boehringer Ingelheim’s request that the agency consider approving Gilotriftm (afatinib) for an additional category of lung cancer patients. Gilotriftm is already approved ... Read more